Cite
HARVARD Citation
Miehlke, S. et al. (2022). Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6‐week open‐label trial of the EOS‐2 Programme. United European Gastroenterology journal. 10 (3), pp. 330-343. [Online].